急性脑梗死采用阿加曲班联合疏血通治疗效果及对神经功能恢复的影响研究

Study on the Effect of Argatroban Combined with Shuxuetong Treatment on Acute Cerebral Infarction and Its Influence on Nerve Function Recovery

目的研究分析急性脑梗死患者采用阿加曲班联合疏血通治疗的效果以及对神经功能恢复的影响。方法于2018年12月—2019年12月方便选取该院接收的88例急性脑梗死患者,作为该次研究之中的观察主体。根据电脑随机分组方法分为两组,每组44例。其中常规组单纯应用阿加曲班治疗,研究组予以阿加曲班联合疏血通治疗。比较两组治疗效果。结果研究组临床治疗后所获得的总体疗效93.18%更高,与常规组的77.27%比较差异有统计学意义(χ^2=4.423,P<0.05)。用药前研究组与常规组NIHSS神经功能缺损评分(20.0±1.02)分vs(20.1±13.7)分差异无统计学意义(t=0.388,P>0.05),用药后研究组与常规组NIHSS神经功能缺损评分明显下降,且研究组(10.3±1.09)分低于常规组(15.1±1.37)分,差异有统计学意义(t=18.190,P<0.05)。研究组不良反应总发生率4.55%与常规组的6.82%比较差异无统计学意义(χ^2=0.000,P>0.05)。结论在阿加曲班基础之上为急性脑梗死患者应用疏血通治疗,不仅临床疗效突出,而且还能够积极改善患者神经功能缺损程度,不良反应未增加,安全性较高。

Objective To study and analyze the effect of argatroban combined with Shuxuetong treatment in patients with acute cerebral infarction and its influence on the recovery of nerve function.Methods From December 2018 to December 2019,88 patients with acute cerebral infarction received in the hospital were conveniently used as the main body of observation in this study.According to the computer randomized grouping method,they were further divided into two groups,each with 44 cases.One group was named the conventional group and was treated with argatroban alone;the other group was named as the research group and was treated with argatroban combined with Shuxuetong.To compare the effect of the two groups.Results The overall efficacy of the study group(93.18%)was higher after clinical treatment,which was significantly different from the conventional group(77.27%),the difference was statistically significant(χ^2=4.423,P<0.05).The NIHSS neurological deficit score(20.0±1.02)points vs(20.1±1.37)points of the study group before medication and the routine group was not statistically significantly different(t=0.388,P>0.05),and the NIHSS neurological deficit score of the study group and the routine group was significant after medication of the study group(10.3±1.09)points was lower than that of the routine group(15.1±1.37)points,the difference was statistically significant(t=18.190,P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the study group(4.55%)and the routine group(6.82%),the difference was statistically significant(χ^2=0.000,P>0.05).Conclusion On the basis of argatroban,the application of Shuxuetong treatment for patients with acute cerebral infarction not only has outstanding clinical efficacy,but also can actively improve the degree of neurological deficits in patients with no increase in adverse reactions and high safety.It is worth clinical large-scale promotion.